Clinical characteristics of patients
| Clinical characteristics of patients (n = 78) . | HLH (n = 38) . | Non-HLH (n = 40) . | P . |
|---|---|---|---|
| Age, mean (range), y | 54 (19-87) | 50.3 (18-89) | .46 |
| Women, n (%) | 11 (28.9) | 23 (57.5) | <.01 |
| No. of HLH criteria fulfilled (mean) | 5.6 | 2.3 | <.005 |
| HScore, median (range) | 215 (83-302) | 87.5 (0-204) | <.005 |
| Elevated sIL-2r >2400 U/mL, n (%) | 38 (100) | 15 (37.5) | <.005 |
| Elevated sIL-2r >10 000 U/mL, n (%) | 17 (44.7) | 3 (7.5) | <.005 |
| Peak ferritin >500 μg/L, n (%) | 38 (100) | 27 (67.5) | <.005 |
| Peak ferritin >10 000 μg/L, n (%) | 30 (78.9) | 13 (32.5) | <.005 |
| Overall mortality, n (%) | 23 (60.5) | 11 (27.5) | <.005 |
| Mortality in patients with sIL-2r >10 000 U/mL (n = 20), n (%) | 11/17 (64.7) | 33 (100) | .52 |
| Mortality in patients with sIL-2r <10 000 U/mL (n = 58), n (%) | 12/21 (57.1) | 837 (21.6) | .006 |
| Clinical characteristics of patients (n = 78) . | HLH (n = 38) . | Non-HLH (n = 40) . | P . |
|---|---|---|---|
| Age, mean (range), y | 54 (19-87) | 50.3 (18-89) | .46 |
| Women, n (%) | 11 (28.9) | 23 (57.5) | <.01 |
| No. of HLH criteria fulfilled (mean) | 5.6 | 2.3 | <.005 |
| HScore, median (range) | 215 (83-302) | 87.5 (0-204) | <.005 |
| Elevated sIL-2r >2400 U/mL, n (%) | 38 (100) | 15 (37.5) | <.005 |
| Elevated sIL-2r >10 000 U/mL, n (%) | 17 (44.7) | 3 (7.5) | <.005 |
| Peak ferritin >500 μg/L, n (%) | 38 (100) | 27 (67.5) | <.005 |
| Peak ferritin >10 000 μg/L, n (%) | 30 (78.9) | 13 (32.5) | <.005 |
| Overall mortality, n (%) | 23 (60.5) | 11 (27.5) | <.005 |
| Mortality in patients with sIL-2r >10 000 U/mL (n = 20), n (%) | 11/17 (64.7) | 33 (100) | .52 |
| Mortality in patients with sIL-2r <10 000 U/mL (n = 58), n (%) | 12/21 (57.1) | 837 (21.6) | .006 |